Skip to main content
. 2018 Jan 6;9(9):8560–8572. doi: 10.18632/oncotarget.24058

Figure 4. EGFRwt is dispensable for EGFRvIII phosphorylation.

Figure 4

(A) AD293 cell lines stably expressing EGFRvIII was treated with erlotinib prior to and simultaneously with NaOVa stimulation. (B) AD293 cell line expressing either naïve or kinase dead (KD) version of EGFRvIII on its own or together with EGFRwt have been treated with EGF or NaOVa, as indicated.